U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C22H24ClFO7
Molecular Weight 454.873
Optical Activity UNSPECIFIED
Defined Stereocenters 5 / 5
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of HENAGLIFLOZIN

SMILES

CCOC1=CC=C(CC2=CC(=CC=C2Cl)[C@@]34OC[C@@](CO)(O3)[C@@H](O)[C@H](O)[C@H]4O)C=C1F

InChI

InChIKey=HYTPDMFFHVZBOR-VNXMGFANSA-N
InChI=1S/C22H24ClFO7/c1-2-29-17-6-3-12(8-16(17)24)7-13-9-14(4-5-15(13)23)22-20(28)18(26)19(27)21(10-25,31-22)11-30-22/h3-6,8-9,18-20,25-28H,2,7,10-11H2,1H3/t18-,19-,20+,21+,22+/m0/s1

HIDE SMILES / InChI

Description

Henagliflozin (also known as SHR3824) was developed by Jiangsu HengRui Medicine as a sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus. This drug successfully passed phase I clinical trials, however, information about further development is not available.

Originator

Approval Year

PubMed

Sample Use Guides

In Vivo Use Guide
to evaluate the pharmacodynamics (PD), pharmacokinetics (PK), safety and tolerability following single and multiple oral doses of 5mg to 20 mg SHR3824 in Type 2 diabetes mellitus patients.
Route of Administration: Oral